82
Participants
Start Date
December 23, 2022
Primary Completion Date
April 1, 2026
Study Completion Date
April 1, 2027
Tafasitamab
Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
Lenalidomide
Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
Clinical Hospital Dubrava, Zagreb
Clinical Hospital Merkur, Zagreb
University Hospital Centre Zagreb, Zagreb
Clinic For Hematology, University Clinical Center Serbia, Belgrade
Turku University Hospital, Turku
Clinic of Hematology Clinical Center of Vojvodina, Novi Sad
Institute For Pulmonary Diseases of Vojvodina, Kamenitz
Coltea Clinical Hospital, Bucharest
Rambam Health Care Campus, Haifa
Mersin University Medical Faculty, Mersin
Tampere University Hospital, Tampere
Clinical Center Kragujevac, Kragujevac
Vkf American Hospital, Istanbul
Marmara Universitesi Pendik Egitim, Istanbul
Ege University Hospital, Izmir
Ercyes University Medical School, Kayseri
Meir Medical Center, Kefar Sava
Tekrda-Nk Tp Fakltesi, Merkez
Kuopio University Hospital, Kuopio
Oulu University Hospital, Oulu
Hadassah University Hospital, Jerusalem
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca
Spitalul Clinic Judetean de Urgenta Targu Mures, Târgu Mureş
Institutul Regional de Oncologie Iasi, Iași
Shaare Zedek Mc, Jerusalem
Medical University Plovdiv, Plovdiv
Acibadem Cityclinica Mhat Tokuda, Sofia
Umhat Alexandrovska Sofia, Sofia
Umhat Sv. Ivan Rilski Ead, Sofia
Specialized Hospital For Active Treatment of Oncological Diseases - Sofia District Eood, Sofia
Fakultni Nemocnice Olomouc, Olomouc
Vseobecna Fakultni Nemocnice, Prague
Aarhus University Hospital, Aarhus
Odense University Hospital, Odense
Helsinki University Central Hospital, Helsinki
Semmelweis Egyetem, Budapest
National Institute of Oncology, Budapest
University of Debrecen, Debrecen
Markhot Ferenc Korhaz, Eger
Somogy Medyei Kaposi Mor Oktato Korhaz, Kaposvár
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Szeged
Bon Secours Hospital, Cork
Mater Misericordiae University Hospital, Dublin
University Hospital Galway, Galway
Akershus University Hospital, Lorenskog
Universitetssykehuset I Trondheim - St. Olavs Hospital, Trondheim
Szpital Uniwersytecki Nr 2 Im Dr. Jana Biziela, Bydgoszcz
Medical University of Gdansk, Gdansk
Szpital Morski Im. Pck Sp. Z O.O, Gdynia
University Public Hospital Nr 1, Lublin
Oddzia Kliniczny Hematologii, Olsztyn
Pratia Poznan, Skórzewo
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego, Wroclaw
Hacettepe University Cancer Institute Clinical Oncology Department, Ankara
Gazi University Hospital Gazi University Faculty of Medicine, Ankara
Ankara University Medical Faculty, Ankara
Ozel Liv Hospital Onkoloji Klinigi, Ankara
Dr. Abdurrahman Yurtaslan Onkology Teaching and Research Hospitalerciyes Universitesi Tip Faklutesi, Yenimahalle
Antrim Area Hospital Northern Health Social Care Trust, Antrim
Belfast Health and Social Care Trust, of Trust Headquarters, Belfast
Lead Sponsor
Incyte Corporation
INDUSTRY